SSSS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SSSS is not a good buy right now for an impatient investor. Despite a longer-term bullish moving-average structure and bullish options positioning, near-term momentum is weakening (MACD turning down, price below pivot) and the largest red flag in the dataset is aggressive insider selling. I would wait for a clearer reversal back above ~9.51 (pivot) or a stronger catalyst (e.g., earnings) before buying.
Trend/momentum is mixed: the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend still leans up, but near-term momentum is fading. MACD histogram is slightly below zero and negatively expanding, indicating downside momentum is building. RSI(6) at ~43.7 is neutral-to-soft (not oversold), so there’s no clear mean-reversion buy signal yet. Price is also below the pivot (9.508), which often acts as a near-term trend line. Key levels: support at S1 ~9.183 (then S2 ~8.983); resistance at R1 ~9.833 (then R2 ~10.033). With regular session down -2.61%, the clean technical setup would be a reclaim of 9.51 and then a push through 9.83; otherwise, risk of probing 9.18/8.98 remains.
Analyst stance is constructive with recent Buy/Outperform calls and a $12 target, framing upside from exposure to high-profile private holdings (e.g., OpenAI-related exposure cited).
Options market skew (very low put-call ratios) indicates traders are generally positioned for upside.
Pattern-based forward stats in the dataset lean positive over 1 week (+3.25%) and 1 month (+7.62%).
Next earnings (2026-02-10 after hours) can be a catalyst if portfolio marks/realizations improve sentiment.
Insider activity is the biggest near-term negative: insiders are selling, with selling amount up sharply (+22763.32% last month), which can cap rallies and hurts confidence in near-term upside.
Near-term technicals are deteriorating (MACD below zero and falling; price below pivot), increasing odds of a dip toward ~9.18/8.98 support.
No supportive news flow in the last week—no fresh catalyst to reverse the current momentum.
Earnings event risk (2026-02-
is two-sided; for an impatient buyer, entering ahead of earnings without a strong technical reversal can be poorly timed.
Latest reported quarter: 2025/Q3. The snapshot shows sharp YoY declines: revenue to 11.33M (-935.85% YoY), net income 7.42M (-236.04% YoY), EPS 0.26 (-213.04% YoY). For an investment/venture-focused vehicle, results can be lumpy due to valuation marks and realizations, but the direction in this quarter is clearly negative versus last year and does not provide a “fundamentals improving right now” tailwind.
Street view in the provided data is positive and strengthening: Barrington (2025-11-05) reiterated Outperform and raised PT to $12 from $11 after Q3, citing portfolio momentum; Lucid Capital (2026-01-05) initiated with Buy and a $12 PT, highlighting differentiated access to emerging private companies. Wall Street pros: potential upside leverage to portfolio winners and private-market exposure. Wall Street cons: results can be highly mark-to-market and volatile (as seen in the latest quarter), and insider selling in the current tape is a notable contradiction to the bullish thesis. Congress/politician trading: no recent data available.
